Global Rivaroxaban Market Growth 2025-2031
Description
The global Rivaroxaban market size is predicted to grow from US$ 9820 million in 2025 to US$ 16030 million in 2031; it is expected to grow at a CAGR of 8.5% from 2025 to 2031.
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
LP Information, Inc. (LPI) ' newest research report, the “Rivaroxaban Industry Forecast” looks at past sales and reviews total world Rivaroxaban sales in 2024, providing a comprehensive analysis by region and market sector of projected Rivaroxaban sales for 2025 through 2031. With Rivaroxaban sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Rivaroxaban industry.
This Insight Report provides a comprehensive analysis of the global Rivaroxaban landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Rivaroxaban portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Rivaroxaban market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Rivaroxaban and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Rivaroxaban.
This report presents a comprehensive overview, market shares, and growth opportunities of Rivaroxaban market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
2.5 mg
10 mg
15 mg
20 mg
Segmentation by Application:
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer
J&J
Key Questions Addressed in this Report
What is the 10-year outlook for the global Rivaroxaban market?
What factors are driving Rivaroxaban market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Rivaroxaban market opportunities vary by end market size?
How does Rivaroxaban break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
LP Information, Inc. (LPI) ' newest research report, the “Rivaroxaban Industry Forecast” looks at past sales and reviews total world Rivaroxaban sales in 2024, providing a comprehensive analysis by region and market sector of projected Rivaroxaban sales for 2025 through 2031. With Rivaroxaban sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Rivaroxaban industry.
This Insight Report provides a comprehensive analysis of the global Rivaroxaban landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Rivaroxaban portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Rivaroxaban market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Rivaroxaban and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Rivaroxaban.
This report presents a comprehensive overview, market shares, and growth opportunities of Rivaroxaban market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
2.5 mg
10 mg
15 mg
20 mg
Segmentation by Application:
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer
J&J
Key Questions Addressed in this Report
What is the 10-year outlook for the global Rivaroxaban market?
What factors are driving Rivaroxaban market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Rivaroxaban market opportunities vary by end market size?
How does Rivaroxaban break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
85 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Rivaroxaban by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Rivaroxaban by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
